MicroRNAs and their delivery in diabetic fibrosis

Alexa Wonnacott, Laura Denby, Richard J M Coward, Donald J Fraser, Timothy Bowen

Research output: Contribution to journalReview article (Academic Journal)peer-review

18 Citations (Scopus)

Abstract

The global prevalence of diabetes mellitus was estimated to be 463 million people in 2019 and is predicted to rise to 700 million by 2045. The associated financial and societal costs of this burgeoning epidemic demand an understanding of the pathology of this disease, and its complications, that will inform treatment to enable improved patient outcomes. Nearly two decades after the sequencing of the human genome, the significance of noncoding RNA expression is still being assessed. The family of functional noncoding RNAs known as microRNAs regulates the expression of most genes encoded by the human genome. Altered microRNA expression profiles have been observed both in diabetes and in diabetic complications. These transcripts therefore have significant potential and novelty as targets for therapy, therapeutic agents and biomarkers.

Original languageEnglish
Pages (from-to)114045
JournalAdvanced Drug Delivery Reviews
Volume182
DOIs
Publication statusPublished - Mar 2022

Bibliographical note

Copyright © 2021. Published by Elsevier B.V.

Keywords

  • Biomarkers
  • Diabetes Complications/drug therapy
  • Diabetic Nephropathies/drug therapy
  • Drug Carriers
  • Fibrosis/drug therapy
  • Humans
  • Hypoglycemic Agents/pharmacology
  • Inflammation/metabolism
  • MicroRNAs/administration & dosage
  • Nanoparticle Drug Delivery System

Fingerprint

Dive into the research topics of 'MicroRNAs and their delivery in diabetic fibrosis'. Together they form a unique fingerprint.

Cite this